• Ioannis Gounaris, Helen M Hatcher, Dochka Davidson, Karen Sherbourne, Salma Alam, Kamarul Ahmad Zaki, Gail Horan, and Helena M Earl.
• Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
• Future Oncol. 2014 Aug 1; 10 (11): 1843-51.

BackgroundWe retrospectively analyzed data from patients who had been treated with trabectedin at our institution between April 2009 and August 2011.Patients & MethodsData from 25 patients with recurrent soft tissue sarcoma (leiomyosarcoma: n = 8; liposarcoma: n = 5) were used to assess the efficacy and safety of trabectedin 1.5 mg/m(2) given every 3 weeks.ResultsMost patients (n = 14) had been heavily pretreated with ≥ 2 previous chemotherapy lines. Eight (32%) patients achieved a partial response according to dimensional and tumor density changes, and seven (28%) patients had stable disease for ≥ 3 months (clinical benefit rate = 60%; n = 15). Median progression-free survival was 6.4 months and overall survival 19.3 months. Common adverse events were fatigue, nausea, anemia and transient transaminase increases.ConclusionTreatment with trabectedin is effective and well tolerated in heavily pretreated soft tissue sarcoma patients. Tapering dexamethasone courses and switching trabectedin administration to an every 4 weeks schedule effectively dealt with persistent fatigue without compromising effectiveness.

34 keywords...

hide…